      





    




!"#$
%&&'(()))*+*(,()!"#$

    -     
./$/,,%0,&&,0
1+23/4.5"
00,&4///

              
      ! "  "      #  $  "$  %& 
    ""  ' ( )     #  $     
 *  %& *  +"        $          $
,   $   %
-.///,  * %(   * %    $ +    +  "   "  
 0    +" " "* 
$  -  *    %

%10&6,,2& ,0

 *!"#$
00,&4///
7 *..3 ..3 ."3#$




,&&%1&8&&,0&%1&8,&%10&6,36&&6
,)+0&&%1&8,0&%+%8%10&681,* %,
91,&%6+&),020,0:06;91&81 1;*
&&.<"<3191011+0,1&8126286&,&8* %,
%,01+0,1&9,,&%&&&&%8,+220&* ,
20& 66 6 2&,&  ,6 &%0& &, +8 2 8& &% % 
,01+0,1&3 82&%&20,,8&6;2,,8&&%%,0*
26,1,&028+2120&,*3+2220&,&%&81
1&&,20,1*

&1&8 1,
&10&% 66
86666#./#
3/5!$$
2 
*=2&10&%*20

1. Introduction
As governments worldwide try to curb their health care costs, policy debates increasingly focus
on the pricing behavior of pharmaceutical firms. Most countries constrain pharmaceutical firms through
direct price regulation. Only a few countries, such as the United States and Germany, allow for product
level price competition and rely on indirect means to reduce pharmaceutical expenditures. The
supporters of price controls justify regulation with the moral hazard problem in prescribing, as physicians
might not internalize the cost of a prescription to the patient or the patientâ€™s insurance provider. They
argue that insurance coverage of prescription pharmaceuticals reduces the sensitivity of physicians and
patients to prices. Yet, little is known whether and how patient insurance affects the pricing behavior of
pharmaceutical firms. This paper investigates this relation.
To my knowledge, there are no other empirical papers examining the link between patient
insurance and pharmaceutical pricing. Several studies provide insights on whether insurance impacts
physician and patient behavior and thus demand for medical services. Hellerstein (1998) investigates the
physicianâ€™s prescription decision between brands and generics, motivated by the puzzle that in 1989, less
than 30% of prescriptions for multi-source drugs specified the generic version even though â€œgenerics are
generally priced 30-60% lower than their trade-name counterparts (p. 108).â€2 She finds that the patient's
insurance plan does not affect the physician's choice between a brand name and a generic product.
However, HMO-affiliated physicians have a higher propensity to prescribe generics irrespective of a
patientâ€™s insurance plan. This pattern could stem from the cost containment measures imposed on
physicians by HMOs. Moreover, studies based on data from the Rand Health Insurance Experiment
document that insurance impacts demand for health services. The experiment randomly assigned

1

Throughout the paper the term Germany refers to the states comprising the Federal Republic of Germany before
reunification.
2
Multi-source drugs are those that are no longer protected by a patent and are available in brand name as well as

2

different cost-sharing plans to individuals and found that the total expenditure (to all parties) on
prescription pharmaceuticals is greater for patients with higher insurance coverage. According to the
study, the participantsâ€™ â€œexpenditures on drugs averaged $65 (in 1991 dollars), ranging from $82 on the
free care plan to $46 on the 95 percent coinsurance plan (Newhouse et.al., p. 165).â€
Given the impact of insurance on physician and patient behavior, my goal is to explore whether
insurance also affects the pricing behavior of pharmaceutical firms. I use a unique policy experiment
from Germany. In 1989, Germany implemented reference pricing, a cost containment scheme that
imposes a maximum reimbursable price to a patient for a given product. 3 Producers are free to set their
prices, but if the retail price exceeds the reference price (RP), the consumer pays the difference.4
Previously, patients paid only a fixed prescription fee regardless of the prescribed medicine. This change
in insurance directly exposes a patient to the price of a medication. The change in insurance modifies the
demand conditions in the market and thus alters the markup that pharmaceutical firms charge over
marginal cost. I evaluate the relationship between insurance and pharmaceutical prices using a detailed
product level data set that spans years before and after the change in insurance and covers several
therapeutic groups. My identification relies on the comparison of prices before and after the reform.
When data permits, I additionally exploit the lag in the implementation of the reform within a therapeutic
group. I then compare the differences in the intertemporal price response of products that compete in a
similar environment, but face different timing in the changes in insurance reimbursement. Finally, I
investigate whether changes in pricing behavior of pharmaceutical firms can be explained by differences
in the competitive pressures firms face.
Germany provides an excellent setting to study the link between insurance and the pricing by
pharmaceutical firms. Unlike the US market with many insurance providers, the German statutory health
insurance covers over ninety percent of the population and always provides coverage for prescription
generic versions.
3
British Columbia, Denmark, the Netherlands, and New Zealand also introduced reference pricing.
4
I explain the reference pricing scheme and other institutional details of German pharmaceutical market in detail in

3

drugs. This setting enables me to address the question without detailed patient level data documenting
their health insurance plan. Additionally, since everybody has the same insurance coverage there is no
selection problem, where people who expect higher medical expenses opt for a more generous insurance
plan. Reliance on country level data could pose a problem if prices differed across various regions and
purchasing outlets as in the United States. German retail pharmacies are the only place permitted to
dispense drugs for outpatient consumers and there is no price variation across them. The government
controls the wholesaler's and retailer's margins, and the prices of the pharmaceuticals dispensed by
pharmacies are uniform by law.
My results suggest that the pricing behavior of pharmaceutical firms is very sensitive to patient
insurance. This finding is robust to different identification strategies and therapeutic markets. The
estimates of price adjustment to exogenous change in insurance range from 10 to 30%. Brand name
products experience the biggest price decline. The price responses by pharmaceutical firms are partially
explained with variation in their exposure to competition. The drop in prices is sharper for those brand
name products that face more generic competition. Policy implications of these results are discussed in
the conclusion of the paper.
The next section presents institutional background on the German pharmaceutical market and the
reference pricing scheme. Section 3 provides theoretical motivation on how changes in insurance might
affect the pricing of pharmaceutical products. Section 4 looks at the data and descriptive statistics.
Section 5 introduces the empirical strategy and discusses the estimation results. Section 6 concludes.
2. Institutional Background on the German pharmaceutical market
In Germany, the retail pharmacies dispense all outpatient care prescription drugs. These retail
pharmacies are the last stage in the distribution of pharmaceuticals from the manufacturer to the patient.
Pharmaceutical manufacturers sell their products to the wholesaler. Manufacturers are free to set their
prices without government approval before and after the implementation of reference pricing. However,

section 2.

4

producers need government approval to launch a new product and must obtain a permit to produce it.
Imported drugs must be licensed and can only be handled by a licensed importer. Moreover, a
manufacturer must sell the product for the same price in a given time period to all wholesalers. The
wholesalers then sell the product to retail pharmacies that deliver it to the patient. The government
controls the wholesaler's and retailer's margins. Thus, by law retail pharmacy prices are uniform across
the country. 5
Insurance plays an important role in the transaction between a patient and the retail pharmacist.
Over ninety percent of the population is covered by statutory health insurance that always includes
coverage for prescription pharmaceuticals. Prior to 1989, patients paid only a fixed prescription fee
when purchasing a pharmaceutical product regardless of the retail price. The 1989 reference pricing
scheme imposes the maximum reimbursable amount (i.e. reference price) for a given product. If the
retail price exceeds the maximum reimbursement, the patient bears the excess cost. Otherwise, the
patient does not need to copay. The consumer continues to pay a DM3 prescription fee only for the
products not subject to a reference price.6 The retail pharmacist is reimbursed directly by the insurance
based on the prescription obtained from the patient. Unlike in the United States, the pharmacist is not
allowed to substitute to a generic product unless the doctor explicitly permits it on the prescription pad.
The dispensed product must match the strength of the active ingredient, the size, and the dosage of the
physician's prescription (Sitzius, pp. 245). I describe how reference prices might affect a physicianâ€™s
prescribing behavior in detail in section 3.
The Federal Commission of Physicians and the Statutory Health Insurance Committee determine
reference prices in two stages. In the first stage, they jointly specify the therapeutic groups that should be

5

The hospital market is completely separate from the retail pharmacy market. Hospitals provide pharmaceuticals
only for inpatient care. They purchase either from the wholesaler or directly from the manufacturer, in which case
they often receive discounts and rebates. For all these reasons, I do not include them in my analysis.
6
In 1993, the prescription fee was extended to all products and it depended on the price of a package: DM3 if retail
price is less than DM30, DM5 if retail price is between DM30 and DM50, and DM7 if retail price exceeds DM50.
Since 1994, prescription fee depends on package size: DM3 for small package, DM5 for medium package, DM7 for
large package.

5

under the reference price system. Thereafter, the insurance committee selects the level of the reference
price for the most common package size in a given active ingredient or therapeutic group. The reference
prices for other package sizes are then adjusted to accommodate differences in package size and doses
(Sullivan, pp. 72). The committee usually sets the reference price below the price of the most expensive
brand, but above the prices of the generics. For example, for the case of glibenclamide in 1990, the
reference price for a package containing 30 3.5 mg pills was DM9.93, while a brand cost DM12.45 and
the generics ranged from DM6.50 upwards. Reference prices are reviewed on an annual basis. Although
the scheme was introduced in 1989, its implementation continued throughout the early 1990s. For
example, in oral antidiabetic group only the products containing the active ingredient glibenclamide
became subject to reference prices in 1989, while some other active ingredients were not covered until
1994. All antiulcerant active ingredients (H2 antagonists), on the other hand, became subject to
reference pricing in 1992. Overall, 50% of the sales on the German pharmaceutical market were covered
by the reference pricing scheme by July 1993. This significantly falls short of the health ministry's plan
to cover 70 to 80% of prescription sales by 1992 (Sullivan, pp. 72-3). By 1996, reference pricing
extended to 75% of the market (ABPI 1996).
Overall, the existence of a single insurance scheme covering most of the population, the retail
pharmacies as the only outlet for the outpatient pharmaceutical products, the exogenous change in
insurance, and the uniformity of prices across the pharmacies make Germany a good setting to study the
impact of the insurance on the pharmaceutical pricing.
3. Theory Motivation
The impact of patient insurance on the pricing behavior by pharmaceutical firms can be
motivated in a model of demand for pharmaceutical products. Changes in insurance affect the demand
conditions prevailing on the market and might alter the markup that pharmaceutical firms charge over
marginal cost.
Let us first consider the decision to consume a pharmaceutical product. Hellerstein (1998)

6

discusses the agency and moral hazard problem in prescribing in detail. The physician acts as an agent
for the patient and prescribes the product probably considering her own cost of prescribing and a
patientâ€™s utility. Based on the prescription, the patient obtains the prescribed medicine from a retail
pharmacy as described in section 2 of the paper. A doctor writing a prescription for a patient with a
particular illness faces a choice among several alternative treatments (active ingredients) in a given
therapeutic group. Additionally, several companies can produce a given active ingredient after patent
expiration or under a licensing agreement, providing an option between brands and generics. A
pharmaceutical product can thus be viewed as a bundle of characteristics that affects patient well being
such as efficacy, safety, reliability, brand name, and price. If a doctor acts as a perfect agent for the
patient, the doctor prescribes the product that yields the highest well being for the patient. This choice
might be altered if it is costly for a doctor to gather information about product prices or other
characteristics.
Patient insurance might affect the doctorâ€™s prescription if the doctor considers the patientâ€™s well
being in prescribing. When patients only perceive a constant prescription fee for all products, the price
of a product does not determine the choice of product relative to other characteristics such as efficacy
and safety unless the doctor is liable for the reimbursement cost of her prescriptions. The new insurance
rules, however, expose the patient to the price pi of product i if iâ€™s price exceeds the maximum
reimbursement level pr. The perceived price that enters the valuation problem is pi âˆ’ pr if pi > pr and
0 otherwise. In the setting of this paper, a physician likely considers the productâ€™s price in her
prescribing decision. Physicians are required by law to inform the patient whether the price of the
prescribed product exceeds the reimbursable level, and physicians can obtain price quotes and reference
prices in Rote Liste. Rote Liste includes pharmacological information such as dosage, side effects, retail
price, and the reference price of pharmaceutical products. It is the most important reference source for
physicians prescribing pharmaceuticals (Sitzius, pp. 247). Physicians can then prescribe a product whose
price does not exceed the reference price rather than a more expensive product if the quality or reliability

7

of the two products does not differ substantively. This might particularly affect the pricing of brands
relative to generics. If brands in a given active ingredient group face generic competition and their
efficacy and reliability do not differ much, the producers of brands might need to decrease their prices to
the level of or around the reference price to protect their market share. Therefore, one would expect a
differential response for brands and generics to insurance change. The price adjustment also might differ
with the level of competition. Products exposed to more competition might be more likely to lower their
price than those without many alternatives. I thus explicitly control for competition when I estimate the
price responses to changes in insurance in section 5.
4. Data and Descriptive Results
The analysis relies on data on oral antidiabetics and antiulcerants (in particular, H2 antagonists)
from IMS Health. 7 The two therapeutic groups are used worldwide to treat widespread illnesses: type II
diabetes (oral antidiabetics) and peptic ulcers (antiulcerants). In addition, both therapeutic groups
provide a choice of various active ingredients and the choice between brands and generics. The two
therapeutic groups differ in that the products in oral antidiabetics have faced generic competition for a
while, while generic products only recently entered the antiulcerant market. The data spans eleven years
from 1986 to 1996 and covers the area comprising the Federal Republic of Germany before reunification.
The original IMS Health database provides quarterly time series information on the value and volume of
retail pharmacy sales for each presentation of a given drug produced by a given manufacturer. In each
time period, I aggregate over various presentations of a given drug produced by a given manufacturer and
define that as a product.8 An observation is then a product-quarter. Since the reference prices are quoted
on the retail level, I perform the analysis with retail prices.9 For each product, I convert the volume of

7

This data source has been used in the studies of the US pharmaceutical market such as Ellison et. al. (1997), ScottMorton (1997), and Stern (1996).
8
For example, drug named x produced by manufacturer y is sold in packages containing 80 75 milligram (mg)
tablets and packages containing 40 150 mg tablets. In each time period, I aggregate the volume (in mg) and revenue
data over these two presentations to obtain the volume and value sold of drug named x produced by manufacturer y.
9
In the original data, sales are reported at the ex-manufacturer's, wholesaler's, and retailer's levels. The government
regulates the wholesalerâ€™s and retailerâ€™s margins, which do not change during the time of my data.

8

sales to the number of average daily doses sold. I obtain that number by dividing the total quantity sold
(in mg) by the average daily dose (in mg) for a specific active ingredient contained in the product.10 This
standardization enables price and quantity comparisons across products with different active ingredients
that belong to the same therapeutic group. As is common in this literature (Stern (1996), Ellison et. al
(1997), Scott-Morton (1997)) the price is obtained by dividing the value of sales by the volume sold.11
Since the volume is measured in the number of daily doses sold, prices thus always refer to the price per
daily dose. All prices are expressed in 1990 (4th quarter) DM using a price deflator from the Datastream
International Database. The data from IMS Health also contains information on a product's active
ingredient, manufacturer, launch date, and whether a product is a brand or a generic. 12 Data on reference
prices and dates of their implementation are obtained from various issues of Rote Liste. They are also
expressed per daily dose. Summary statistics for the variables are provided in Table 1.
The rest of this section illustrates a drop in prices of oral antidiabetics and antiulcerants after the
imposition of maximum insurance reimbursement. The fundamental finding that remains robust to all
specifications in this paper is evident here: producers significantly reduce their prices after the changes
in insurance. Figures 1a and 1b plot the average price of brand name and generic oral antidiabetics
affected by reference pricing since 1989 and 1994, respectively. Figures 1a and b display a pronounced
drop in the average price of brands that coincides with the introduction of the new insurance scheme in
1989 and 1994, correspondingly. The average price of the generics does not change as much. Figure 1c
plots the same information for antiulcerants that received RP in 1992. The average price of brands has
been declining over time in general, but does so faster after 1991 when generic products enter the market.
10

If the average patient requires 2 75mg tablets twice per day, then the average daily dose is 300mg. If a firm sells
80 75mg tablets of a given product, this is equivalent to 20 daily doses sold. Average patient daily doses are
obtained from the pharmacological reference Martindale.
11
Given the disaggregated nature of data and the lack of coupons or rebates, the use of sales revenue per daily dose
rather than the actual price is not problematic. Even if I had actual price rather than sales data, I would need to
transform it to a measure of price per daily dose to make meaningful comparisons across products.
12
Brand name products include products marketed by the original firm that patented the active ingredient, their
parallel imports, and any brand name product sold by another firm under the terms of a license agreement with the
originator. This also includes products that are marketed by the distributor, a company that does not manufacture the
product and markets them under the same trade name as the originator.

9

There is a sharper drop in prices in 1992. The average price of generics also follows the same pattern.
Although the decreases in average prices coincide with the implementation of changes in insurance
reimbursement, other time varying factors such as the number of generics could affect the prices in the
two markets. Given the recent introduction of generic products this poses a particular concern for
antiulcerants. Moreover, since 1993 doctors are liable financially if the total cost of their prescriptions
exceeds a certain budget. In my estimation I control for this change in various ways, but the results
obtained with the data for oral antidiabetics up to 1992 provide the cleanest experiment when assessing
the impact of patient insurance on pharmaceutical pricing. Moreover, since the change in 1993 may also
lower the prices of pharmaceutical products, it might bias the results that consider changes in insurance
in 1994 against finding any impact. In my analysis in section 5, I develop several empirical strategies to
control for all these factors in identifying the impact of insurance on firm pricing.
5. Empirical Analysis
5.1 Empirical Implementation
The preliminary evidence from the previous section is consistent with producers reacting to
changes in insurance reimbursement. This section proposes several approaches to identify the effect of
insurance on the pricing behavior of pharmaceutical firms. Since I observe product level market
outcomes before and after the change in insurance, I first focus my analysis only on the variation of
prices over time. Consider the following semi logarithmic regression specification
(1)

ln( pijt ) = Î± + Î² postt + Î³ brandi + Î² 2 (brandi * postt ) + m j + Îµ ijt

where pijt is the price of a product i with an active ingredient j at time t, postt is an indicator whether time
t is covered by reference pricing, and mj is an indicator for whether a product contains an active
ingredient j. Îµijt could represent a measurement error in prices or unobserved factors that affect prices.
brandi is an indicator whether product i has a brand name, and the interaction between brandi and postt
denotes a brand sold after the imposition of reference prices. Equation (1) captures the institutional
features important to pharmaceutical industry. The relevant market consists of products in a therapeutic

10

group that is used for treatment of a particular disease. I thus estimate equation (1) separately for oral
antidiabetics and antiulcerants. Each therapeutic group provides several possible therapeutic alternatives
(active ingredients). In order to control for the differences in therapeutic value of available active
ingredients, active ingredient indicators are included in all of the regression specifications. Several
companies might produce the same active ingredient either after patent expiration or under a licensing
agreement. I therefore distinguish between generics and brands. Within this framework, if no
uncontrolled factors that affect prices vary before and after the changes in insurance, the coefficient Î² on
the post indicator depicts the impact of changes in insurance on the pricing of firms producing generic
products. The interaction between the brand and the post indicator allows the effects of the
reimbursement policy to differ for brand-name products. If the coefficient Î²2 is negative, the brands
lower their prices more after the change in insurance than the generics.
These estimates that rely on the variation of prices before and after the reimbursement change to
identify the impact of insurance on pricing might be biased by intertemporal variation not related to
changes in insurance such as changes in technology, regulation, or demand. Alternatively, I can compare
the pricing of products affected by reference prices, the treatment group, to a control group of products
subject to the same technology, regulatory, and demand shocks as the treatment group, but not subject to
reference pricing. Because of the lag in the implementation of reference pricing (RP), some active
ingredients in oral antidiabetics did not face RP until 1994, and they represent a good control for
products with RP since 1989. Similarly, products without RP in 1994 present a control for oral
antidiabetics with RP since 1994. I estimate the following specification:

(2)

ln( pijt ) = Î± + Î² postt + Âµ rpi + Î³ brandi + Î´ (rpi * postt ) + Î»1 (brandi * postt )
+ Î»2 (brandi * rpi ) + Î´ 2 (rpi * brand i * postt ) + m j + Îµ ijt

where indicator rpi denotes whether a product i belongs to the treatment group--products subject to a
reference price. All other notation follows that of (1). In this setting the variable post controls for
factors that change concurrently with the change in insurance and affect products with and without

11

reference prices. The coefficient on the interaction of the indicator for products with a reference price rpi
and post, Î´, is the estimate of the impact of the changes in insurance on generics. The coefficient on the
interaction of the reference price indicator rp, brand indicator brand, and post, Î´2, is the estimate of the
additional insurance impact on the pricing of brands.
An alternative way to study the effect of insurance on pharmaceutical pricing is to relate product
prices to the actual insurance reimbursement levels, i.e. reference prices, using observations after the
implementation of insurance reform. 13 Table 2 reports the results of regressing prices on reference
prices (both in logs) for oral antidiabetics and antiulcerants. The regressions always include active
ingredient indicators and either a time trend or year indicators, and they are estimated using product
random effects.14 The results suggest that producers respond sharply to changes in patient
reimbursement. Conditional on the product having a reference price, a drop in reimbursement leads to a
significant decline in prices. The elasticity estimates are around .3 for oral antidiabetics, suggesting that
as reimbursement declines by 10%, prices drop by 3%. The estimates range from .1 to .16 for
antiulcerants. Overall, this approach only uses the observations after the implementation of the reform
and might be more believable if there is significant variation in reimbursement levels over time. In my
data, the observations do not span a long time frame after the insurance change. For example, for many
oral antidiabetics I only have 2 years of observations. Also, although reference prices are reviewed on an
annual basis, their levels often do not change at all or by much in practice. In oral antidiabetics no major
adjustment occurred between 1989 and 1994, while reference prices changed quite significantly for some
antiulcerants in 1994 and 1996. I thus do not incorporate the actual reimbursement level in the rest of the
analysis and rely on price variation before and after the implementation of insurance changes.

13

The observations dating prior to reference pricing cannot be used in the analysis. The reimbursement level equals
the product's price prior to the imposition of reference pricing, so the dependent variable would appear as an
explanatory variable. Rather than including the reference price level directly one could use the patient's required
payment. Since the payment equals the actual product price less the reference price after the imposition of RP, this
would force one to include the product's price (the depended variable) as a regressor for observations in periods with
reference prices. Moreover, patientâ€™s required payment was constant across time and products prior to RP.
14
Hausman tests fail to reject that the regressors are not correlated with the error term in all cases.

12

5.2 Empirical Results
I begin by discussing several estimation issues before presenting the results of (1) and (2). First,
my data consists of repeated observations on the same product i over time, so I need to adjust standard
errors for the correlation in the error terms across observations on product i. A time invariant unobserved
product characteristic (such as unobserved quality) that affects prices might be correlated also with
regressors. Hausman tests fail to reject that the regressors are not correlated with the error term in all of
the reported regressions in this paper, so the random effects estimation (a GLS estimator allowing for
correlation in errors for the same product across different periods) yields consistent and efficient
estimates of the coefficients. All of the reported results in the paper use this specification.
Second, my analysis relies on intertemporal variation before and after the change in insurance.
In order to check the robustness of my results to unobserved time varying factors that impact prices, I
compare results without time controls to results with a time trend and results with year indicators in (1)
and (2). Without time controls, I attribute all uncontrolled intertemporal variation in prices before and
after the reform to changes in insurance. The second approach of including a time trend assumes that
changes in insurance lead to a price shift but do not affect the price trend. The third approach with year
indicators identifies the effect of insurance using the average variation in prices before and after the
reform.
I first focus the discussion of results on oral antidiabetics. They present a relatively stable and
established market during my sample. The first active ingredient was introduced in the 1940s. Thus,
they are less likely to incur significant changes in the competitive environment or technological shocks
concurrently with insurance changes. Table 3 reports the estimates of (1) for oral antidiabetics with
various time controls. Columns 1-3 do not distinguish between brands and generic products. If all
uncontrolled factors affecting prices remain constant before and after the change in insurance, the
coefficient on the post indicator depicts the average percentage change in prices as a result of changes in
insurance. The negative coefficients in columns 1-3 suggest that pharmaceutical prices drop significantly

13

after the change in insurance. The estimates range from 15 to 23%.
Because of the gradual implementation of new insurance rules for oral antidiabetics, I am able to
estimate the impact of insurance relying on both variation over time and a control group as in (2). As
mentioned earlier, some active ingredients in oral antidiabetics do not face RP until 1994, and they
represent a good control group for products with RP since 1989. Similarly, products still without RP in
1994 present a control for oral antidiabetics with RP since 1994. These results are reported in table 4.
Column 2 of table 4 reports the estimates of equation (2) for oral antidiabetics subject to maximum
reimbursement since 1989 using observations up to 1992. Prices declined on average by 10.9% as a
result of the 1989 insurance change. This estimate is very close to the one obtained in the simple before
and after analysis reported in column 1 (-9.5%). Similar findings are obtained for oral antidiabetics
subject to new insurance rules since 1994 reported in columns 5 and 6 using observations from 1992 to
1996. There, the estimated impact of insurance relying on control group (-26.1%) is lower than the
estimate based on the intertemporal variation (-34.4%). These findings persist when the regressions
include no time controls or a time trend. The results are presented in appendix tables 1 and 2,
respectively.
Figures 1a and 1b and the theoretical motivation in section 3 of the paper suggest that brands and
generic products might adjust differentially to insurance changes. Columns 4-6 of table 3 report
estimates of equation (1) differentiating between generic products and brands using various time
controls. Brands reduce their prices significantly more than generics. For example, column 6 indicates
that the prices of generic products decline on average by 11.5% after the change in insurance. Although
the prices of brands are on average 52.7% higher than those of generics prior to changes in insurance, the
brand premium declines after the reform. The prices of brands drop on average by an additional 25.9%.
These finding are robust to the inclusion of a control group as in (2). The estimates of (2) for oral
antidiabetics subject to new insurance rules since 1989 (1994) are reported in column 4 (column 8) of
table 4. They are close to those obtained by the simple before and after analysis reported in column 3

14

(column 7). For example, column 3 and 4 both suggest that the generic products drop their prices by
5.7% as a result of insurance change in 1989. When I rely on a control group in column 4, the estimate
suggests that brands decrease prices by an additional 33.6% after the change in insurance. This is close
to the estimate of 29.5% relying solely on intertemporal variation in column 4.15
Overall, my results suggest that prices respond sharply to declines in insurance reimbursement.
My estimates also confirm the anecdotal evidence that reimbursement changes affect brands and generics
differently. Zweifel and Crivelli (1996) suggest that the reform produced an immediate decline in prices
of innovators to the reference price level, but had little impact on generic prices, which were already
below the reimbursement ceiling. Sullivan (1993), on the other hand, claims that generic producers
increased prices so that the reform decreased price competition. This could, for example, occur if
changes in insurance facilitate collusion among generic producers by providing a focal point, from which
firms are less likely to deviate. I find that the prices of generic products drop in most cases, but that the
drop is on average much more pronounced for brands. This suggests that producers need to significantly
decrease the premium for a brand name product to protect their market shares as patients actually
perceive the price of a product.
As oral antidiabetics are a market with no major changes in competitive environment, the
estimates of the relationship between insurance and price are not very sensitive to whether and how I
control for other time varying variables. Antiulcerants, however, have undergone significant changes in
market environment. Generic products only enter the market in 1991, a year prior to insurance change
and the increased presence of generic products might impact prices independently of insurance changes.
The estimates of the link between insurance and pricing that do not control for generic competition are
unsurprisingly less robust than those for oral antidiabetics. For example, table 5 reports the estimates of
a version of (1) for antiulcerants using various time controls. The coefficients on post indicator vary
significantly across specification with different time controls. The decrease in prices range from 46%

15

Appendix tables 1 and 2 show that these results are robust to inclusion of a time trend or no time controls.

15

when all intertemporal variation is attributed to changes in insurance, to 12% when we include year
indicators, to none when a time trend is included. Moreover, the coefficient on post indicator is sensitive
to the choice of the base year when I include year indicators. Since all antiulcerants became subject to
the maximum reimbursement level at the same time in 1992, I need to exclude two year indicators. In
column 3, I exclude the year prior to the implementation of the reform (1991) and the first year of the
reform (1992), which is equivalent to renaming the year indicator for the initial year of insurance change
as post. The effect of insurance (the coefficient on post) is thus identified solely by the variation in
prices in the first year of the reform relative to the previous year. Column 4, on the other hand, excludes
the initial year of the sample (1986) and the first year of the reform, so that the coefficient on post is
identified by the variation in prices in the first year of the reform relative to the initial year of the sample.
Unsurprisingly, the coefficient in column 4 (-.27) exceeds the estimated effect of insurance in column 3
(-.12). Given these caveats, I explicitly incorporate the changes in competition in section 5.3 in the
analysis of insurance and pricing for antiulcerants.
5.3 Competition
In this section I first check whether the decline in prices of pharmaceutical products after the
change in insurance persists when I directly control for the competitive environment. I then examine
whether the differences in competition products face elucidate the differential response of products to
changes in insurance. I control for competition by augmenting equation (1) with a variable measuring the
number of generics in the active ingredient group. This measure of competition has been, for example,
used by Scott-Morton (1997). I also interact number of generics with the post indicator and a brand
indicator to allow differential impact of competition before and after changes in insurance and for
brands. The number of generics facing a product in a given active ingredient group could be a function
of a product's price. For example, more generics might enter the market segment with higher prices
because of higher anticipated profits. Also, there might be unobserved factors that affect product prices
and generic entry. Hence, to identify the effect of generic competition on price, I need variables that

16

affect a producerâ€™s ability to enter a pharmaceutical market that do not directly affect the prices of
existing products. The endogeneity problem in the case of this paper is mitigated because the entry of
generics is determined by past prices and patent expiration dates as it takes time to acquire a production
permit or an importer's license. Also, if the endogeneity issue arises because higher prices lead to greater
entry of generics, this suggests a positive correlation between prices and generic competition. If we are
interested in whether additional generic competition lowers prices, this form of a bias attenuates the true
effect and might result in a false rejection of the hypothesis. Alternatively, if the endogeneity arises from
an unobserved time-invariant characteristic affecting both prices and competition, the product fixed
effects estimation would yield unbiased estimates. Using a Hausman test, I do not reject the hypothesis
that the regressors are not correlated with the error term, and I therefore continue using a random effects
model.
The estimates of equation (1) augmented with the number of generics are reported in table 6 for
antiulcerants. This table controls for the unobserved time-varying factors with year indicators and relies
on the variation in prices in the initial year of the reform relative to the year preceding the reform.
Appendix tables 3, 4, and 5 estimate the augmented equation (1) using no additional time controls,
adding a time trend, and adding year indicators and using 1986 as a base year. After controlling for
generic competition, the findings across the specifications with various time controls do not differ, so I
focus my discussion on table 6. Columns 1-4 of table 6 report the results based on all antiulcerant
products. In columns 5-12, I check the robustness of results using only products containing the active
ingredient that became subject to generic competition in 1991.
The comparison of the effect of insurance in columns 1 and 2 illustrates the importance of
controlling for generic competition in this changing market. Column 1 suggests that prices declined on
average by 11.5% after the change of insurance and that brands did not change their prices differently
from generics. Conditioning on the number of generics in column 2 halves the impact of insurance on
prices to around 5.8%. Similar pattern is obtained in columns 5 and 6 using only products with the active

17

ingredient subject to generic competition since 1991. Overall, conditional on the number of generic
products, the 1992 change in insurance does not impact product prices significantly. Moreover, the
negative coefficient on the number of generics in column 2 and 6 suggests that additional generic
competition lowers prices. One could argue that it is difficult to pinpoint the impact of the 1992
insurance change even after controlling for generic competition given that the generic products entered
the market in 1991. Products containing the active ingredient with generic competition since 1991 also
experienced a large reduction in the assigned reference price in 1994. By then, more generic competition
existed. In columns 9-12, I focus on the 1994 insurance change using data for 1992 to 1996. The post
indicator is thus one if the time period is covered by the 1994 insurance change and zero otherwise.
Column 9 suggests a decline in the price of generics and an additional decline in the price of brands after
the reimbursement change. Conditional on the number of generics, the price of a generic product
actually increases on average after the change in insurance, while insurance has a small negative impact
on the pricing of brands (column 10). Table 7 repeats the above analysis for oral antidiabetics.16 The
impact of insurance on the pricing of generics and brands continues to persist even after controlling for
the number of generics. For example, the estimates of the impact of insurance in column 1 are very close
to those in column 6 of table 3 that do not explicitly control for generic competition.
Given the importance of generic products in the antiulcerant market, I next check whether
generic competition influences the price response of products to changes in insurance. If products lower
their prices because they effectively face more price competition from generics after the changes in
insurance, the coefficient on the interaction between the number of generics and the post indicator should
be negative. The results for antiulcerants in table 6 support this hypothesis. Columns 3, 7, and 11 allow
the number of generics to affect prices differently before and after the insurance change. Columns 7 and
11 indicate that everything else equal, the additional generic competition lowers product prices more
after the change in insurance. The coefficient on the interaction of post and the number of generics is
16

Appendix table 6 repeats the analysis for oral antidiabetics with a time trend or with no time controls. The

18

negative.17 The importance of generic competition is even more pronounced for brands: the coefficient
on the interaction of post indicator, brand, and the number of generics is always negative and significant
(columns 4, 8, 12). This finding is also confirmed in column 3 of table 7 for oral antidiabetics. After the
changes in insurance, the brands are no longer able to change as high of a brand premium as when all the
products are subject to a constant prescription fee. The brands facing more generic competition reduce
their price premium by more after the change in insurance.18
Given the large price response to changes in insurance found in this paper, it is interesting to
observe a lack of response in the quantity of products sold. Table 8 reports estimates of (1) with
quantities as a dependent variable. The coefficient on the post variable is insignificant for oral
antidiabetics and antiulcerants in column 1 and 3. Moreover, while the quantity sold for generics on
average stays the same (oral antidiabetics) or increases (antiulcerants), the quantity sold of brands on
average declines after changes in insurance. This confirms that the producers of brand name products
have an incentive to lower prices to shield their market share. Although the change in insurance alters
the mix of quantities sold between generics and brand name products, it does not halt the growth in the
overall market size. Figures 2a and 2b trace the total quantity sold (measured in number of daily doses
sold) over time in the oral antidiabetics and antiulcerant market, respectively. Both markets in general
continue to grow despite the cost containment measures. For example, although the sales of oral
antidiabetics drop sharply right after the change in insurance in 1989, the quantities recover shortly
thereafter. The initial decline is likely due to the sluggish price adjustment in the first two quarters of
1989 observed in Figure 1a. No such sharp quantity response is evident after the insurance changes for

conclusions are the same.
17
In column 3, the additional generic competition lowers prices, but this effect is not significantly different before
and after the insurance change.
18
As a robustness check, I have repeated the analysis in tables 6 and 7 using a Herfindahl index as a measure of
competition in an active ingredient group. A market segment with a higher Herfindahl index is more concentrated
and less competitive. The Herfindahl index and the number of generics in a given active ingredient group are thus
likely inversely related. Given that the correlation between the Herfindahl index and the number of generics is -.89
for oral antidiabetics and -.86 for antiulcerants, it is not surprising that the estimates based on the Herfindahl index
yield the same conclusions.

19

oral antidiabetics in 1994 (figure 2a) and for antiulcerants in 1992 (figure 2b). The lack of response
might imply that producers have learnt about the price sensitivity of patients from 1989 changes in
insurance and lower their prices immediately after the subsequent reimbursement adjustments.
6. Conclusion
This paper examines a unique episode of exogenous changes in insurance to assess the link
between insurance and pricing behavior by pharmaceutical firms. I find that producers significantly
reduce prices as the change in insurance reimbursement directly exposes patients to prices. Depending
on the therapeutic group and specification, the estimates of price reductions due to changes in insurance
range from 10 to 30%.
Generic competition seems to play an important role in this process. The changes in
reimbursement mostly affect price competition between brands and generics within the same active
ingredient group. Brands reduce their prices on average by 13 to 30% more than generics, and the price
drop is bigger for brands containing an active ingredient facing more generic competition. This
corroborates the findings by Ellison et. al. (1997) that the relevant competition in the pharmaceutical
market occurs between generics and the brand name version of the same active ingredient rather than
across products that are therapeutics substitutes, i.e. products with different active ingredients, but
belonging to the same therapeutic group. Their model of pharmaceutical demand yields high estimates of
cross-price elasticities among generics and brands with the same active ingredient and low estimates of
cross-price elasticities between products with different active ingredients. The lack of competition
between therapeutic substitutes is also found by Scott-Morton (1997). She investigates how the OBRA
legislation affects the pricing by pharmaceutical firms in the US market.19 Scott-Morton finds the
legislation does not substantively alter the pricing of patented products because of relatively weak
competition from their therapeutic substitutes.
19

The legislation requires that the pharmaceutical firms give Medicaid price discounts based on the lowest (or at
times average) price that other buyers negotiate with pharmaceutical firms. The theory predicts that the law should
diminish the firmâ€™s incentives to lower prices for more price sensitive consumers, because the firm must extend such

20

Moreover, my results strongly suggest that patients and doctors are sensitive to insurance.
Recent studies of pharmaceutical demand abstract from insurance coverage. A more explicit treatment of
insurance in these empirical models might be a fruitful area for future research.
Most importantly, this paper shows that changes in patient insurance spillover to the
pharmaceutical producers. This channel should not be ignored when discussing the implications of
expanding health insurance coverage. For example, recent debates in the United States about whether
Medicare should cover outpatient prescription pharmaceuticals often conclude with demands for the
direct price regulation of pharmaceuticals. Public interest in these debates in not surprising given that
pharmaceuticals account for 30 percent of out-of pocket expenditures for health services in the United
States in 1992, and the elderly account for 35 percent of total drug consumption (Schweitzer 1997). A
carefully designed insurance reimbursement scheme for outpatient pharmaceuticals might provide an
alternative to direct price regulation. However, lower prices might dissuade pharmaceutical firms from
cross subsidizing research intensive activities as the producers might be less likely recoup their R&D
investment. Clearly, future research should identify this tradeoff between lower pharmaceutical prices
and R&D investment.

benefits to Medicaid.

21

Bibliography
ABPI (1996). Summary of Pricing and Reimbursement Measures Taken by European Countries Since
January 1993, mimeo.
Danzon, Patricia M (1997). Pharmaceutical price regulation: national policies versus global interests.
Washinton, D.C.: The AEI Press.
Ellison, Sara Fisher, et. al. (1997). "Characteristics of Demand for Pharmaceutical Products: An
examination of Four Cephalosporins," RAND Journal of Economics 28, pp. 426-446.
Hellerstein, J.K. (1998). "The importance of the physician in the generic versus trade-name prescription
decision," RAND Journal of Economics 29, pp. 108-136.
Manning, Willard G., et. al. (1987). â€œHealth Insurance and the Demand for Medical Care: Evidence from
a Randomized Experiment,â€ American Economic Review 77, pp. 251-277.
Martindale: The Extra Pharmacopoeia (The Royal Pharmaceutical Society) 31st edition, Ed. James E.F.
Reynolds. London, 1996.
Newhouse, Joseph P. and the Insurance Experiment Group (1993). Free for All? Lessons from the RAND
Health Insurance Experiment. Cambridge, MA: Harvard University Press.
Rickwood, Sarah (1994). Pharmaceutical Pricing: International Strategies. London: Financial Times
Business Information.
Rote Liste, various years.
Schweitzer, Stuart O. (1997). Pharmaceutical Economics and Policy. New York: Oxford University
Press.
Scott-Morton, Fiona (1997). â€œThe strategic response by pharmaceutical firm to the Medicaid mostfavored-customer rules," RAND Journal of Economics 28, pp. 269-290.
Sitzius-Zehender, Hannelore (1992). "Federal Republic of Germany," in Richard N. Spivey, et. al. (eds.)
International pharmaceutical services: the drug industry and pharmacy practice in twenty-three
major countries of the world. New York: Pharmaceutical Products Press.
Stern, Scott (1996). "Product Demand in Pharmaceutical Markets," mimeo, MIT Sloan School.
Sullivan, Kevin (1993). "Recent legislative changes in Germany," in Pricing and Reimbursement of
Pharmaceuticals, EPLC Pharma Law Report No 7.
Zweifel, Peter and Luca Crivelli (1996). "Price Regulation of Drugs: Lessons from Germany," Journal
of Regulatory Economics 10, pp 257-273.

22

0

2

4

6

8

.2

.3

.4

.5

88

90
year

92

86
year

92

diamondâ€”generics

90

94

94

96

96

0

.5

1

1.5

86

88

90
year

92

1b-Oral Antidiabetics with RP since 1994

Note: The vertical line depicts the year insurance changed for a given product.
Source: IMS Health, Rote Liste, authorâ€™s own calculations.

88

1c--Antiulcerants with RP since 1992

86

1a-Oral Antidiabetics with RP since 1989

circleâ€”brands,

Avg. Retail Prices

Avg. Retail Prices

Figure 1-Average Price of Brands and Generics with RP

Avg. Retail Prices

94

96

1.1e+08

1.2e+08

1.3e+08

1.4e+08

86

88

2a-Oral Antidiabetics

90
year

92

94

96

1.0e+07

2.0e+07

3.0e+07

4.0e+07

5.0e+07

86

88

2b--Antiulcerants

90
year

92

94

Note: The vertical line depicts the year RPs were introduced for a given product.
Source: IMS Health, Rote Liste, authorâ€™s own calculations.

Number of DD Sold

Figure 2-- Number of Daily Doses Sold

Number of DD Sold

96

Table 1--Summary Statistics
Variable

N

Mean

S.D.

Min

Max

Price of Average Daily Dose

2051

0.49

0.45

0.07

2.26

Share of Brands

2051

0.24

0.43

0

1

374

6.53

9.65

0

32

Price of Average Daily Dose

1347

4.10

2.22

0.72

8.37

Share of Brands

1347

0.58

0.49

0

1

193

2.95

7.28

0

29

Oral Antidiabetics

Number of Generics per Active Ingredient
Antiulcerants

Number of Generics per Active Ingredient

Note: Prices in 1990 DM. Source: IMS Health, CPI is from Datastream. N is the number of quarterproducts. N is the number of quarter-active ingredients in the case of the number of generics per active
ingredient.

Table 2--The Effect of Insurance Reimbursement on Pricing
(dependent variable is log retail price)

Oral Antidiabetics
(1)
(2)
ln(reference price)
Year indicators
Time trend
Active Ingredient Indicator
N

Antiulcerants
(3)
(4)

.289 **
(.101)

.328 **
(.116)

.105 **
(.050)

.164 **
(.070)

no
yes
yes

yes
no
yes

no
yes
yes

yes
no
yes

1029

1029

941

941

Note: Standard errors are in parenthesis. ** and * indicate significance at a 5% and 10%
level, respectively. All regressions are estimated using product random effects. Retail
prices and reference prices are measured per average daily dose.

no
yes
yes
1834

yes
no
yes
1834

-.259 **
(.024)

.527 **
(.160)

.537 **
(.163)
-.280 **
(.024)

-.115 **
(.019)

(6)

-.085 **
(.017)

(5)

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and *
indicate significance at a 5% and 10% level, respectively. All regressions are estimated using product random effects. The
indicator variable post is 1 for 1989 and after except for products that become subject to reference prices in 1994. For these
products the post indicator is zero through 1993. Brand is one if product has a brand name and zero otherwise. 1986 is the
omitted year indicator.

yes
no
yes
1834

no
no
yes
1834

no
yes
yes
1834

Year indicators
Time trend
Active Ingredient Indicators
N

no
no
yes
1834

-.284 **
(.024)

(.019)

-.169 **
(.012)

(4)

Brand*Post

(.016)

(.010)

-.187 **

(3)

.515 **
(.168)

-.150 **

-.229 **

(2)

Brand (yes=1)

Post

(1)

(dependent variable is log retail price)

Table 3--The Effect of Insurance on Pricing for Oral Antidiabetics

yes
na
726

(.023)

-.095 **

.733 **

yes
yes
1272

yes
na
726

(.037)

-.295 **

yes
no
429

(.100)

(.037)

yes
no
1272

-.170 *

-.336 **

yes
no
304

(.300)

.821 **

(.256)

.366

(.069)

-.189 **

(.160)

-.409 **

(.067)

-.085

(.090)

(.051)

-.181 **

(.191)

1.185 **

(.044)

-.262 **

(.023)

yes
yes
429

(.051)

-.261 **

(.374)

-1.965 **

(.051)

-.095 **

-.012

yes
yes
304

(.038)

-.344 **

.040

(.291)

.020 *

(.150)

.713 **

(.018)

(.015)
(.266)

-.057 **

(.118)

-.109 **

-1.070 **

(.018)

-.014

(.390)

(.023)

-.057 **

-1.644 **

(.017)

.000

RP since 1994 using 1992-1996
(5)
(6)
(7)
(8)

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a
5% and 10% level, respectively. All regressions are estimated using product random effects. Post is one if the time period is after the imposition of
reference prices. In columns 1-4, the indicator variable post is one if the time period is after the imposition of reference prices (1989 and after). In
columns 5-8, the indicator variable post is one if the time period is after the imposition of reference prices (1994 and after). RP is one if the product
belongs to the treatment group. So, RP is one if the product is covered by reference prices since 1989 (columns 1-4) , or by reference prices since
1994 (columns 5-8). Brand is one if product has a brand name and zero otherwise.

Year indicators
Active ingredient indicators
N

RP*brand*post

RP*brand

brand*post

brand (yes=1)

RP *post

RP (yes=1)

post

RP since 1989 using 1986-1992
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Table 4--The Effect of Insurance on Pricing for Oral Antidiabetics with reference prices since 1989 or 1994

Table 5--The Effect of Insurance on Pricing for Antiulcerants
(dependent variable is log retail price)

Post

Year indicators
Time trend
Active Ingredient Indicators
N

(1)

(2)

(3)

(4)

-.463 **

.010

-.122 **

-.274 **

(.016)

(.021)

(.021)

(.030)

no
no
yes
1347

no
yes
yes
1347

yes
no
yes
1347

yes
no
yes
1347

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard
errors are in parenthesis. ** and * indicate significance at a 5% and 10% level, respectively.
All regressions are estimated using product random effects. The indicator variable post is 1
for 1992 and after. Brand is one if product has a brand name and zero otherwise. The
omitted year indicators in column 3 are 1991 and 1992. The omitted year indicators in
column 4 are 1986 and 1992.

-.011

yes
yes
1347

**

.482

yes
yes
1347

yes
yes
1347

(.015)

-.059

(.015)

.055

.056
(.014)

(.014)

-.064

(.127)

.002

**

.464
(.130)

(.004)

(.004)

-.013

-.022

(.001)

**

**

**

**

**

**

**

**

na
yes
882

-.069 *
(.042)

na
yes
882

(.003)

-.025

(.042)

.012

.702 ** .617
(.081)
(.082)

-.101 ** -.027
(.037)
(.037)

**

**

na
yes
882

(.007)

-.021

(.005)

-.013

(.044)

-.028

(.084)

.656

(.074)

.176

**

**

**

**

RP in 1992 (1986-1996)
(5)
(6)
(7)

na
yes
882

(.015)

-.069

(.015)

.059

(.014)

.035

(.014)

-.064

(.130)

.651

(.143)

.210

(.130)

-.353

(8)

**

**

**

**

**

*

**

na
yes
646

na
yes
646

(.005)

-.033

-.137 ** -.131
(.032)
(.030)

.725 ** .714
(.072)
(.072)

-.108 ** .116
(.025)
(.041)

**

**

**

**

na
yes
646

(.010)

-.051

(.006)

-.016

(.030)

-.138

(.072)

.718

(.213)

1.174

**

**

**

**

**

na
yes
646

(.010)

-.021

(.008)

.006

(.011)

-.044

(.007)

-.019

(.205)

.333

(.128)

.646

(.225)

1.004

RP in 1994 (1992-1996)
(9)
(10)
(11)
(12)

**

**

**

**

**

**

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a 5% and 10% level, respectively. All
regressions are estimated using product random effects. Columns 1-4 are estimated using all antiulcerants. Columns 5-12 are estimated using only products with the active ingredient
that had generic competitors since 1991. This is the same active ingredient that underwent a significant decline in reference price in 1994. Columns 1-8 consider the effect of insurance
change in 1992 on pricing using data from 1986 to 1996. For those columns, the indicator variable post is 1 for 1992 and after. The omitted year indicators in columns 1-8 are 1991
and 1992, so that the effect of insurance is identified with the variation in prices in 1992 relative to 1991. Columns 9-12 consider the impact of additional change in insurance for the
active ingredient in question in 1994 using data from 1992 to 1996. For those columns, the indicator variable post is 1 for 1994 and after. The omitted year indicators in columns 9-12
are 1993 and 1994, so that the effect of insurance is identified with the variation in prices in 1994 relative to 1993. Brand is one if product has a brand name.

Active Ingredient Indica
yes
Year Indicators
yes
N
1347

ngen*post*brand

ngen*brand

ngen*post

Number of generics (ngen)

.898
(.060)
(.044)

-.005
(.040)

brand*post

**

-.550
(.125)

-.076
(.050)

-.034

.910 ** .909
(.057)
(.056)

brand (yes=1)

*

(.038)

-.115 ** -.058
(.037)
(.035)

post

RP in 1992 (all products 1986-1996)
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Table 6--The effect of insurance on pricing for Antiulcerants

Table 7--The effect of insurance on pricing for Oral Antidiabetics
(dependent variable is log retail price)

post
brand (yes=1)
brand*post
Number of generics (ngen)

(1)

(2)

(3)

-.131 **

-.260 **

-.552 **

(.020)

(.036)

(.048)

.509 **

.446 **

.857 **

(.163)

(.162)

-.243 **

-.173 **

(.025)

(.030)

(.051)

-.007

-.019 **

(.006)

(.006)

.011 **
(.004)

ngen*post

.007 **
(.002)

ngen*brand

(.337)

.198 **

.020 **
(.002)

-.009
(.012)

ngen*post*brand

-.018 **
(.003)

Active Ingredient Indicators
Year Indicators

yes
yes

yes
yes

yes
yes

Note: Retail prices are expressed per daily dose and measured in 1990 DM.
Standard errors are in parenthesis. ** and * indicate significance at a 5% and
10% level, respectively. All regressions are estimated using product random
effects. The indicator variable post is 1 for 1989 and after except for products
that obtain RP in 1994. For these products the post indicator is zero through
1993. Brand is one if product has a brand name and zero otherwise. N is 1834.

yes
yes
1347

-.144
(.207)

(3)

yes
yes
1347

-1.987 **
(.269)

.861 *
(.523)

1.754 **
(.328)

Antiulcerants
(4)

yes
na
882

-2.298 **
(.307)

1.563 **
(.743)

1.467 **
(.394)

(5)

Note: Quantity is measured in number of daily doses sold. Standard errors are in parenthesis. ** and * indicate
significance at a 5% and 10% level, respectively. All regressions are estimated using product random effects. For oral
antidiabetics, the indicator variable post is 1 for 1989 and after except for products that obtain RP in 1994. For these
products the post indicator is zero through 1993. For antiulcerants, the indicator variable post is 1 for 1992 and after.
Brand is one if product has a brand name and zero otherwise. Column 5 only includes products containing the active
ingredient with generics in 1991. The omitted year indicators in columns 3-5 are 1986 and 1992.

yes
yes
1834

Year indicators
Active Ingredient Indicators
N

yes
yes
1834

-.492 **
(.109)

Brand*Post

.124
(.087)
.248
(1.092)

-.013
(.082)

Brand (yes=1)

Post

Oral Antidiabetics
(1)
(2)

(dependent variable is log quantity sold)

Table 8--The Effect of Insurance on Quantity Sold

no
na
726

-.089 **

no
yes
1272

no
na
726

(.037)

-.297 **

(.281)

-.303 **

-.051

-.248 **

(.244)

.650 **

(.207)

.380 *

(.042)

-.218 **

(.116)

-.370 **

no
no
429

(.070)

(.037)

no
no
1272

-.096

-.334 **

no
no
304

-.033
(.041)

(.064)

(.032)

-.123 **

(.153)

1.029 **

(.028)

(.023)

no
yes
429

(.033)

-.254 **

(.321)

-1.776 **

(.033)

-.027

no
yes
304

(.024)

.037

(.298)

.025

(.153)

.709 **

-.058 **
(.018)

-.109 **
(.015)

(.121)

(.402)

.733 **

-.031 **
(.015)

-1.073 **

(.013)

-1.640 **

-.018
(.012)

-.126 **
(.013)

RP since 1994 using 1992-1996
(5)
(6)
(7)
(8)

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a
5% and 10% level, respectively. All regressions are estimated using product random effects. Post is one if the time period is after the imposition of
reference prices. In columns 1-4, the indicator variable post is one if the time period is after the imposition of reference prices (1989 and after). In
columns 5-8, the indicator variable post is one if the time period is after the imposition of reference prices (1994 and after). RP is one if the product
belongs to the treatment group. So, RP is one if the product is covered by reference prices since 1989 (columns 1-4) , or by reference prices since
1994 (columns 5-8). Brand is one if product has a brand name and zero otherwise.

Year indicators
Active ingredient indicators
N

RP*brand*post

RP*brand

brand*post

brand (yes=1)

RP *post

RP (yes=1)

post

RP since 1989 using 1986-1992
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Appendix Table 1--The Effect of Insurance on Pricing for Oral Antidiabetics with reference prices since 1989 or 1994 using no time
controls

-.094 **

yes
na
726

(.024)

.001

-.061 **

yes
yes
1272

yes
na
726

(.037)

-.296 **

(.285)

-.222 **

.025

-.141 **

(.293)

.806 **

(.249)

.372

(.069)

-.199 **

(.156)

-.405 **

yes
no
429

(.101)

(.037)

yes
no
1272

-.157

-.334 **

yes
no
304

.041
(.069)

(.091)

(.052)

-.181 **

(.185)

1.179 **

(.052)

(.023)

yes
yes
429

(.051)

-.264 **

(1.163)

1.851

(.054)

-.025

yes
yes
304

(.047)

.038

(.296)

.023

(.152)

.710 **

-.058 **
(.018)

-.109 **
(.015)

(.121)

(.404)

.732 **

-.015
(.019)

-1.071 **

(.024)

-1.078 **

(.017)

RP since 1994 using 1992-1996
(5)
(6)
(7)
(8)

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a
5% and 10% level, respectively. All regressions are estimated using product random effects. Post is one if the time period is after the imposition of
reference prices. In columns 1-4, the indicator variable post is one if the time period is after the imposition of reference prices (1989 and after). In
columns 5-8, the indicator variable post is one if the time period is after the imposition of reference prices (1994 and after). RP is one if the product
belongs to the treatment group. Thus, RP is one if the product is covered by reference prices since 1989 (columns 1-4) , or by reference prices since
1994 (columns 5-8). Brand is one if product has a brand name and zero otherwise.

Time Trend
Active ingredient indicators
N

RP*brand*post

RP*brand

brand*post

brand (yes=1)

RP *post

RP (yes=1)

post

RP since 1989 using 1986-1992
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Appendix Table 2--The Effect of Insurance on Pricing for Oral Antidiabetics with reference prices since 1989 or 1994 using a time
trend

-.076
(.050)

brand*post

yes
no
1347

yes
no
1347

(.001)

-.024

(.038)
**

*

**

**

**

.093

yes
no
1347

yes
no
1347

(.016)

-.034

(.016)

.043

.033
(.016)

(.016)

-.064

(.139)

.000

**

.637
(.145)

(.004)

(.004)

-.025

(.049)

-.070

(.075)

.985

-.284
(.138)

-.083
(.051)

**

**

**

**

**

**

na
no
882

na
no
882

(.001)

-.033

-.131 ** .087
(.056)
(.039)

.872 ** .547
(.112)
(.080)

-.384 ** .027
(.051)
(.037)

**

**

**

na
no
882

(.004)

-.018

(.004)

-.017

(.046)

-.030

(.083)

.660

(.051)

.191

**

**

**

RP in 1992 (1986-1996)
(5)
(6)
(7)

na
no
882

(.015)

-.059

(.015)

.050

(.015)

.033

(.014)

-.064

(.134)

.546

(.144)

.278

(.128)

-.277

(8)

**

**

**

**

**

**

**

na
no
646

na
no
646

(.003)

-.043

-.131 ** -.115
(.038)
(.031)

.747 ** .705
(.073)
(.071)

-.315 ** .173
(.024)
(.035)

**

**

**

**

na
no
646

(.005)

-.040

(.004)

-.020

(.030)

-.137

(.071)

.717

(.100)

.941

**

**

**

**

**

na
no
646

(.010)

-.021

(.008)

.005

(.006)

-.033

(.005)

-.022

(.205)

.339

(.127)

.647

(.123)

.779

RP in 1994 (1992-1996)
(9)
(10)
(11)
(12)

**

**

**

*

**

**

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a 5% and 10% level, respectively.
All regressions are estimated using product random effects. Columns 1-4 are estimated using all antiulcerants. Columns 5-12 are estimated using only products with the active
ingredient that had generic competitors since 1991. This is the same active ingredient that underwent a significant decline in reference price in 1994. Columns 1-8 consider the effect
of insurance change in 1992 on pricing using data from 1986 to 1996. For those columns, the indicator variable post is 1 for 1992 and after. Columns 9-12 consider the impact of
additional change in insurance for the active ingredient in question in 1994 using data from 1992 to 1996. For those columns, the indicator variable post is 1 for 1994 and after.
Brand is one if product has a brand name.

Active Ingredient Ind.
Year Indic. or Trend
N

ngen*post*brand

ngen*brand

ngen*post

Number of generics (ngen)

1.156 ** .988
(.091)
(.071)

brand (yes=1)
-.071

-.384 ** -.081
(.047)
(.038)

post

RP in 1992 (all products 1986-1996)
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Appendix Table 3--The effect of insurance on pricing for Antiulcerants--Robustness Check

yes
yes
1347

yes
yes
1347

yes
yes
1347

(.004)

-.012 **

-.003
(.004)

-.016 **
(.001)

.412 **
-.025 **

-.007 *

-.064 **

(.015)

.062 **

(.014)

.042 **

(.014)

yes
yes
1347

na
yes
882

-.071 **

na
yes
882

(.004)

-.019 **

(.004)

.648 **
(.131)

(.015)

na
yes
882

(.002)

-.026
(.045)

.183
(.143)

-.062 **

na
yes
882

.102
(.038)

.657 **
(.083)

-.343 **
(.126)

(.015)

(.015)

.065 **

(.015)

.046 **

(.014)

-.064 **

(.131)

.216 **
(.051)

(8)
.157 **
(.035)

.962 **
(.125)

.796 **
(.145)

na
yes
646

na
yes
646

(.005)

-.025 **

na
yes
646

(.006)

-.041 **

(.005)

-.020 **

na
yes
646

(.010)

-.021 **

(.008)

.005

(.007)

-.034 **

(.006)

-.023 **

-.131 ** -.121 ** -.138 ** .338 *
(.032)
(.031)
(.030)
(.205)

.720 ** .708 ** .717 ** .647 **
(.071)
(.070)
(.071)
(.127)

.055 *
(.030)

RP in 1994 (1992-1996)
(9)
(10)
(11)
(12)

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a 5% and 10% level, respectively.
All regressions are estimated using product random effects. Columns 1-4 are estimated using all antiulcerants. Columns 5-12 are estimated using only products with the active
ingredient that had generic competitors since 1991. This is the same active ingredient that underwent a significant decline in reference price in 1994. Columns 1-8 consider the effect
of insurance change in 1992 on pricing using data from 1986 to 1996. For those columns, the indicator variable post is 1 for 1992 and after. Columns 9-12 consider the impact of
additional change in insurance for the active ingredient in question in 1994 using data from 1992 to 1996. For those columns, the indicator variable post is 1 for 1994 and after.
Brand is one if product has a brand name.

Active Ingredient Ind.
Time Trend
N

ngen*post*brand

ngen*brand

ngen*post

Number of generics (ngen)

-.042
(.045)

.083 *
(.043)

.120 ** .045
(.040)
(.037)

.036
(.037)

brand*post

-.047
(.040)

.828 ** .849 ** .933 ** .423 ** .581 ** .534
(.064)
(.082)
(.061)
(.065)
(.134)
(.079)

-.361 **
(.128)

brand (yes=1)

.104 **
(.049)

-.081 ** -.006
(.039)
(.036)

RP in 1992 (1986-1996)
(5)
(6)
(7)

post

RP in 1992 (all products 1986-1996)
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Appendix table 4--The effect of insurance on pricing for Antiulcerants--Robustness Check

yes
yes
1347

yes
yes
1347

(.001)

-.011
**

.464

yes
yes
1347

yes
yes
1347

(.015)

-.059

(.015)

.055

.056
(.014)

(.014)

-.064

(.127)

.482

(.130)

.002

**

-.652
(.129)

(.004)

(.004)

-.013

-.022

**

**

**

**

**

**

**

**

**

na
yes
882

-.069 *
(.042)

na
yes
882

(.003)

-.025

(.042)

.012

.702 ** .617
(.081)
(.082)

-.247 ** -.049
(.054)
(.059)

**

**

na
yes
882

(.007)

-.021

(.005)

-.013

(.044)

-.028

(.084)

.656

(.074)

.094

**

**

**

RP in 1992 (1986-1996)
(5)
(6)
(7)

na
yes
882

(.015)

-.069

(.015)

.059

(.014)

.035

(.014)

-.064

(.130)

.651

(.143)

.210

(.138)

-.470

(8)

**

**

**

**

**

**

**

na
yes
646

na
yes
646

(.005)

-.033

-.137 ** -.131
(.032)
(.030)

.725 ** .714
(.072)
(.072)

-.210 ** .167
(.027)
(.061)

**

**

**

**

na
yes
646

(.010)

-.051

(.006)

-.016

(.030)

-.138

(.072)

.718

(.203)

1.148

**

**

**

**

**

na
yes
646

(.010)

-.021

(.008)

.006

(.011)

-.044

(.007)

-.019

(.205)

.333

(.128)

.646

(.216)

.977

RP in 1994 (1992-1996)
(9)
(10)
(11)
(12)

**

**

**

*

**

**

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate significance at a 5% and 10% level, respectively.
All regressions are estimated using product random effects. Columns 1-4 are estimated using all antiulcerants. Columns 5-12 are estimated using only products with the active
ingredient that had generic competitors since 1991. This is the same active ingredient that underwent a significant decline in reference price in 1994. Columns 1-8 consider the effect
of insurance change in 1992 on pricing using data from 1986 to 1996. For those columns, the indicator variable post is 1 for 1992 and after. The omitted year indicators in columns 18 are 1986 and 1992, so that the effect of insurance is identified with the variation in prices in 1992 relative to 1986. Columns 9-12 consider the impact of additional change in
insurance for the active ingredient in question in 1994 using data from 1992 to 1996. For those columns, the indicator variable post is 1 for 1994 and after. The omitted year indicators
in columns 9-12 are 1992 and 1994, so that the effect of insurance is identified with the variation in prices in 1994 relative to 1992. Brand is one if product has a brand name.

Active Ingredient Ind.
Year Indicators
N

ngen*post*brand

ngen*brand

ngen*post

Number of generics (ngen)

.898
(.060)
(.044)

-.005
(.040)

brand*post

**

-.164
(.052)

-.034

.910 ** .909
(.057)
(.056)

brand (yes=1)

**

(.038)

-.261 ** -.152
(.049)
(.047)

post

RP in 1992 (all products 1986-1996)
(1)
(2)
(3)
(4)

(dependent variable is log retail price)

Appendix Table 5--The effect of insurance on pricing for Antiulcerants with a different comparison group

no
no
yes

(.004)

(.003)

no
no
yes

(.001)

.010 **

-.020 **

(.030)

(.025)

-.002

-.167 **

(.161)

.419 **

-.287 **

(.164)

.520 **

(.031)

(.015)

no
yes
yes

no
yes
yes

(.003)

(.003)

no
no
yes

-.017 **

-.017 **

-.010

(.002)

.019 **

(.005)

-.012 **

(.049)

.172 **

(.338)

.865 **

(.045)

-.521 **

(.012)

(.001)

.008 **

(.005)

-.005

(.029)

-.172 **

(.161)

.439 **

(.034)

-.260 **

(6)

-.010

no
yes
yes

(.004)

.011 **

(.025)

-.262 **

(.164)

.518 **

(.017)

-.099 **

(5)

(.012)

(.002)

.021 **

(.004)

-.026 **

(.050)

.183 **

(.341)

.860 **

(.043)

-.616 **

-.355 **

-.162 **

(4)

Note: Retail prices are expressed per daily dose and measured in 1990 DM. Standard errors are in parenthesis. ** and * indicate
significance at a 5% and 10% level, respectively. All regressions are estimated using product random effects. The indicator
variable post is 1 for 1989 and after except for products that obtain RP in 1994. For these products the post indicator is zero
through 1993. Brand is one if product has a brand name and zero otherwise. N is 1834.

Year Indicators
Time trend
Active Ingredient Indicators

ngen*post*brand

ngen*brand

ngen*post

Number of generics (ngen)

brand*post

brand (yes=1)

post

(3)

(2)

(1)

(dependent variable is log retail price)

Appendix Table 6--The effect of insurance on pricing for Oral Antidiabetics--Robustness Check

